Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: RXGOLF who wrote (14076)	2/2/1998 3:24:00 PM
From: tonyt	Read Replies (1) \| Respond to of 32384

Re: Jubak's Journal Had this been posted? I don't remember seeing it: (Apologies if this is a repeat) investor.msn.com New Developments on Past Columns: Stocking Up On Biotechs It hasn't taken much in the way of bad news to move a biotech stock down recently. And most good news isn't moving shares up significantly. Face it -- no one wants to buy illiquid small-company stocks in this uncertain market. Ligand Pharmaceuticals (LGND) is down about 20% since I recommended it on Oct. 28. One of the company's partners, Pfizer (PFE), halted development on the drug Droloxifene for use against breast cancer, but will continue working on the drug for use in osteoporosis. Since Ligand was set to collect only a very low 1% royalty, loss of this potential application isn't significant financially, but was probably enough to hurt the stock. Isis Pharmaceuticals (ISIP) is on track to file a new drug application with the Food & Drug Administration for fomivirsen, its drug for CMVretinitus. The stock is down about 9